Compare Indoco Remedies with NESCO LIMITED - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs NESCO - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES NESCO INDOCO REMEDIES/
NESCO
 
P/E (TTM) x 129.8 20.8 623.8% View Chart
P/BV x 2.2 3.2 68.1% View Chart
Dividend Yield % 0.6 0.5 133.3%  

Financials

 INDOCO REMEDIES   NESCO
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
NESCO
Mar-19
INDOCO REMEDIES/
NESCO
5-Yr Chart
Click to enlarge
High Rs317605 52.5%   
Low Rs178405 44.0%   
Sales per share (Unadj.) Rs113.151.0 221.5%  
Earnings per share (Unadj.) Rs4.525.6 17.4%  
Cash flow per share (Unadj.) Rs11.827.3 43.3%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %0.40.5 81.5%  
Book value per share (Unadj.) Rs73.2166.1 44.1%  
Shares outstanding (eoy) m92.1570.46 130.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.29.9 22.1%   
Avg P/E ratio x55.519.7 281.2%  
P/CF ratio (eoy) x21.018.5 113.3%  
Price / Book Value ratio x3.43.0 111.3%  
Dividend payout %22.49.8 229.3%   
Avg Mkt Cap Rs m22,83035,582 64.2%   
No. of employees `0005.50.2 3,430.8%   
Total wages/salary Rs m2,209183 1,205.2%   
Avg. sales/employee Rs Th1,910.122,616.9 8.4%   
Avg. wages/employee Rs Th405.01,152.8 35.1%   
Avg. net profit/employee Rs Th75.511,347.2 0.7%   
INCOME DATA
Net Sales Rs m10,4193,596 289.7%  
Other income Rs m47331 14.2%   
Total revenues Rs m10,4663,927 266.5%   
Gross profit Rs m1,3492,314 58.3%  
Depreciation Rs m677119 570.4%   
Interest Rs m23547 499.2%   
Profit before tax Rs m4842,479 19.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m72675 10.7%   
Profit after tax Rs m4121,804 22.8%  
Gross profit margin %12.964.4 20.1%  
Effective tax rate %15.027.2 55.0%   
Net profit margin %4.050.2 7.9%  
BALANCE SHEET DATA
Current assets Rs m5,373703 764.6%   
Current liabilities Rs m4,157906 458.8%   
Net working cap to sales %11.7-5.7 -206.3%  
Current ratio x1.30.8 166.7%  
Inventory Days Days689 739.1%  
Debtors Days Days7318 397.6%  
Net fixed assets Rs m6,2447,220 86.5%   
Share capital Rs m184141 130.8%   
"Free" reserves Rs m6,56611,564 56.8%   
Net worth Rs m6,75011,705 57.7%   
Long term debt Rs m1,2330-   
Total assets Rs m12,36313,487 91.7%  
Interest coverage x3.153.6 5.7%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.3 316.1%   
Return on assets %5.213.7 38.1%  
Return on equity %6.115.4 39.6%  
Return on capital %9.021.6 41.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,7622 202,274.2%   
Fx outflow Rs m1,1430 408,357.1%   
Net fx Rs m2,6192 165,753.2%   
CASH FLOW
From Operations Rs m1,2271,708 71.8%  
From Investments Rs m-1,360-1,548 87.9%  
From Financial Activity Rs m-388-198 195.7%  
Net Cashflow Rs m-521-37 1,395.7%  

Share Holding

Indian Promoters % 59.2 61.8 95.8%  
Foreign collaborators % 0.0 1.8 -  
Indian inst/Mut Fund % 12.5 4.9 255.1%  
FIIs % 6.0 8.7 69.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 22.9 97.8%  
Shareholders   12,805 12,392 103.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   TATA INVESTMENT  CCL INTERNATIONAL  S.P. APPARELS  CREST VENTURES  EDELWEISS FINANCIAL  



Today's Market

Sensex Trades Marginally Higher; Tata Steel & Bajaj Finance Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note, tracking gains in global peers. US President Donald Trump said he did not want war.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

NESCO 2018-19 Annual Report Analysis (Annual Result Update)

Jul 10, 2019 | Updated on Jul 10, 2019

Here's an analysis of the annual report of NESCO for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of NESCO. Also includes updates on the valuation of NESCO.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

NESCO Announces Quarterly Results (4QFY19); Net Profit Up 20.1% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NESCO has posted a net profit of Rs 514 m (up 20.1% YoY). Sales on the other hand came in at Rs 935 m (up 23.8% YoY). Read on for a complete analysis of NESCO's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 18, 2019 12:31 PM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS